Volumetric (3D) bladder dose parameters are more reproducible than point (2D) dose parameters in vaginal vault high-dose-rate brachytherapy

Lucas Gomes Sapienza1,2, Adriana Flosi1, Antonio Aiza3, Antonio Cassio de Assis Pellizzon1, Rubens Chojniak3 & Glauco Baiocchi4

There is no consensus on the use of computed tomography in vaginal cuff brachytherapy (VCB) planning. The purpose of this study was to prospectively determine the reproducibility of point bladder dose parameters (D\textsubscript{ICRU} and maximum dose), compared with volumetric-based parameters. Twenty-two patients who were treated with high-dose-rate (HDR) VCB underwent simulation by computed tomography (CT-scan) with a Foley catheter at standard tension (position A) and extra tension (position B). CT-scan determined the bladder ICRU dose point in both positions and compared the displacement and recorded dose. Volumetric parameters (D\textsubscript{0.1cc}, D\textsubscript{1.0cc}, D\textsubscript{2.0cc}, D\textsubscript{4.0cc} and D\textsubscript{50%}) and point dose parameters were compared. The average spatial shift in ICRU dose point in the vertical, longitudinal and lateral directions was 2.91 mm (range: 0.10–9.00), 12.04 mm (range: 4.50–24.50) and 2.65 mm (range: 0.60–8.80), respectively. The D\textsubscript{ICRU} ratio for positions A and B was 1.64 (p < 0.001). Moreover, a decrease in D\textsubscript{max} was observed (p = 0.016). Tension level of the urinary catheter did not affect the volumetric parameters. Our data suggest that point parameters (D\textsubscript{ICRU} and D\textsubscript{max}) are not reproducible and are not the ideal choice for dose reporting.

Postoperative vaginal cuff brachytherapy (VCB) with or without external beam radiation therapy (EBRT) is an integral component of the adjuvant treatment of endometrial cancer\textsuperscript{1}, and this combination is an option in certain cases of cervical cancer\textsuperscript{2}.

The documentation of the dose to organs at risk (OARs) during gynecological intra-cavitary brachytherapy was formally stated by the International Commission on Radiation Units and Measurements (ICRU) in 1985\textsuperscript{3}. Published in 2006\textsuperscript{4}, the Groupe Européen de Curiethérapie (GEC) and the European Society for Radiotherapy and Oncology (ESTRO) recommendations for 3D image-based brachytherapy, directed to cervical cancer, advocate documentation of the dose to the bladder with the ICRU reference point and D\textsubscript{0.1cc}, D\textsubscript{1.0cc} and D\textsubscript{2.0cc} (volumetric parameters). In 2012, the American Brachytherapy Society (ABS) published a consensus guideline on recommendations for VCB\textsuperscript{5}, including reporting the dose to adjacent organs, particularly the bladder and rectum, but did not specify the exact parameters.

Currently, the choice between point dose parameters, such as ICRU bladder point dose (D\textsubscript{ICRU}) and maximum bladder dose (D\textsubscript{max}), and volumetric parameters relies solely on dosimetric evidence\textsuperscript{6–11}. Several studies have compared ICRU and volumetric dose, but the lack of a relation or difference between them prevents either from being recommended over the other. Thus, evidence of the superiority of 3D planning in terms of predicting toxicity over 2D planning—or a technical limitation of the 2D planning—must be provided to justify the use of volumetric parameters in the post-hysterectomy setting.

1Department of Radiation Oncology, A.C. Camargo Cancer Center, São Paulo, 01509-010, Brazil.
2Department of Radiation Oncology, Clínicas Oncológicas Integradas (COI-RJ), Rio de Janeiro, 22793-080, Brazil.
3Department of Radiology, A.C. Camargo Cancer Center, São Paulo, 01509-010, Brazil.
4Department of Gynecologic Oncology, A.C. Camargo Cancer Center, São Paulo, 01509-010, Brazil.
Correspondence and requests for materials should be addressed to L.G.S. (email: lgsapienza@yahoo.com.br)
Our aim was to prospectively demonstrate the limitations in reproducing conventional point-based dosimetry after comparing bladder volumetric dose parameters with bladder point dose parameters in the treatment of vaginal apex treatment, using two different tension levels for positioning of the Foley catheter.

**Results**

Twenty-two patients were prospectively enrolled in this study between June 2014 and February 2015, totaling 44 CT scans (22 in position A and 22 in position B). Seventeen subjects had endometrial cancer (11 stage I, 1 stage II, 5 stage III), and 5 had cervical cancer (4 stage I and 1 stage II). Fifteen patients received EBRT + BT (53% tri-dimensional conformal radiation therapy and 47% intensity-modulated radiation therapy), and 7 received BT alone. The diameter of the cylinder was 26 mm in 36.4% of patients and 30 mm in 63.6%, according to patient anatomy. Two patients received para-aortic irradiation. There were no complications that were related to insertion of the Foley catheter at the time of the CT scan. The patients were treated with the catheter in standard position.

Data from all 44 treatment plans were available for analysis. None of the parameters (in terms of average doses) was normally distributed.

**Comparison between point dosimetry and volumetric dosimetry.** Based on a normalized dose value (based on the percentage of the prescribed dose), the average $D_{ICRU}$ documented in position A was 2.68 Gy, comprising 44.6% of the total prescribed dose.

Compared with standard tension, the bladder $D_{ICRU}$ value differed significantly from Dmax ($p < 0.0001$), with a Dmax/$D_{ICRU}$ ratio of 2.32. The same results were seen with the volumetric parameters and in comparison with position B (Table 1).

**Impact of Foley catheter tension on dose parameters.** Considering position A as the reference, significant displacement of the balloon center to position B was observed in the longitudinal direction. The average shift in the vertical, longitudinal and lateral directions was 2.91 mm (range: 0.10–9.00), 12.04 mm (range: 4.50–24.50) and 2.65 mm (range: 0.60–8.80), respectively. Figure 1 shows the spatial displacement in each patient, based on position A, which is defined as (0, 0, 0) in the 3D graph.

With respect to reproducibility, the average $D_{ICRU}$ was 2.68 Gy (44.6%) in position A and 1.63 Gy (27.1%) in position B ($p < 0.001$). The $D_{ICRU}$ ratio between positions A and B was 1.64. A significant decrease in maximum dose ($p = 0.016$) was also observed. For the other parameters, the position A/B ratio was 1.023 (D0.1cc), 1.006 (D1.0cc), 1.005 (D2.0cc), 1.032 (D4.0cc) and 1.027 (D50%). The percentage change in each parameter is listed in Table 2.

### Table 1. Comparison between ICRU bladder dose point and other bladder dose parameters.

| Parameter | With standard tension | With extra tension |
|-----------|-----------------------|--------------------|
| $D_{ICRU} \times D_{max}$ | $p < 0.001$ | $D_{ICRU} \times D_{max}$ | $p < 0.001$ |
| $D_{ICRU} \times D_{0.1cc}$ | $p < 0.001$ | $D_{ICRU} \times D_{0.1cc}$ | $p < 0.001$ |
| $D_{ICRU} \times D_{1.0cc}$ | $p = 0.001$ | $D_{ICRU} \times D_{1.0cc}$ | $p < 0.001$ |
| $D_{ICRU} \times D_{2.0cc}$ | $p = 0.003$ | $D_{ICRU} \times D_{2.0cc}$ | $p < 0.001$ |
| $D_{ICRU} \times D_{4.0cc}$ | $p = 0.020$ | $D_{ICRU} \times D_{4.0cc}$ | $p < 0.001$ |
| $D_{ICRU} \times D_{50\%}$ | $p < 0.001$ | $D_{ICRU} \times D_{50\%}$ | $p < 0.001$ |

**Figure 1. 3D scatterplot of catheter spatial displacement between positions A and B.**
Discussion

This study is the first controlled analysis that addresses the limitations of bladder point dosimetric data, in terms of reproducibility. Earlier reports on vaginal vault treatment have merely evaluated the differences between the averages values of ICRU bladder point dose and volumetric parameters; thus, this drawback of point dosimetry argues in favor of 3D planning.

Although the use of CT scan for dose calculation in VCB is attractive, no study has proven the superiority of volumetric data against classical ICRU points with regard to predicting urinary toxicity, necessitating a discussion of the cost-effectiveness of planning with tridimensional imaging in VCB compared with simple x-ray due to the minimal optimization of the applicators13–15, lack of clinical correspondence of the reported dose16 and significant rise in procedure costs7.

The ICRU 38 states that “the catheter is pulled downwards to bring the balloon against the urethra”3. This orientation is fundamental to the localization of the ICRU bladder point, since this document claims that “on the lateral radiograph, the reference point is obtained on an anterior-posterior line drawn through the center of the balloon. The reference point is taken on this line at the posterior surface of the balloon. On the frontal radiograph, the reference point is taken at the center of the balloon”. In this setting, due to the possible variation between different physicians, or even between different insertions performed by the same physician, our study evaluated the impact of various levels of tension (A-standard vs B-extra tension) on catheter spatial position and dose reported to the bladder.

The documented spatial change in the catheter exceeded 10 mm in 1 or more directions in 68% of the patients, translating into an overall reduction in the ICRU bladder point dose of 39% (44.6% to 27.1% of the prescribed dose) and confirming our hypothesis that an intrinsic limitation of the ICRU bladder point dosimetry in terms of reproducibility can lead to a bias. Additionally, Dmax, another point dose analysis, was also significantly affected by catheter position but to a lower extent (5% absolute reduction). Notably, the volume-based parameters were not influenced, with the exception of D50%. These findings could be explained by the hypothesis that the different tension level applied altered the balloon position (changing the ICRU measurement) but not the bladder anatomic position (determined by the constant volumetric doses) in relation to the high-dose region.

Two studies compared DICRU versus volumetric bladder dose that was reported by computed tomography planning using a single-lumen vaginal cylinder in the vaginal apex. Russo et al.6 published a retrospective dosimetric study, analyzing the Dmax and D2cc of the first 20 patients who were treated with CT-based 3D planning after a departmental policy change toward this method. They compared the doses to ICRU bladder point that was recorded from 71 patients who had been previously treated in the same institution, based on plain-film orthograde radiographs. The average normalized bladder dose (as percentage of prescribed dose) was significantly higher with Dmax (x1.78) but not D2cc (x1.08), compared with DICRU. These differences might be attributed to the lack of 2D and 3D information being collected from the same patients.

In the second study, Hung et al.9 prospectively examined the dosimetric effects of bladder filling on OARs and noted a reduction in D2cc values for the small bowel but not the bladder. As expected, the D50% (dose received by 50% of bladder volume) was significantly reduced with a full bladder, due to the increase in volume. Using a similar method as ours, after simulation of the ICRU point position on CT images, they recorded a mean D2cc/ DICRU ratio of 0.95. The difference in mean DICRU between an empty and full bladder was 16 cGy and corresponded to an increase of 1.3% increase with an empty bladder (p-value not provided). These findings suggest the reproducibility of the ICRU point regarding bladder filling. Table 3 compares the characteristics of these studies.

In our series, the same physician delineated the OARs to limit the discrepancies in contouring between assistants. One possible limitation of our study was the absence of a CT scan in every insertion, because possible changes in bladder filling4–10 or rectal filling11 might have influenced the reported dose to the OARs. Moreover, Hoskin et al.17 documented that the angulation of the cylinder can also alter the dose in the bladder and rectum. It’s reasonable to hypothesize that the extra-tension could act as another source of displacement of vaginal vault, which was not controlled in our analysis, but should be tested in future studies. However, other studies suggest that the evaluation of the first insertion is sufficient in terms of dose reporting5,18; this is the current approach at our institution. Another limitation is the absence of a documented manometer reading, which can measure various levels of tension and help reproduce the findings of our study. The normalization that was performed by Russo et al.6, based on the prescribed dose as the denominator, is recommended for studies that compare different dose

| Parameters | Foley catheter tension (normalized*) | Standard tension | Extra tension | % change | p value |
|------------|-------------------------------------|-----------------|--------------|----------|---------|
| DICRU      | 44.6                               | 27.1            | 39.2         | <0.001   |         |
| Dmax       | 103.5                              | 98.3            | 5.0          | 0.016    |         |
| D0.1cc     | 88.1                               | 86.1            | 2.3          | 0.123    |         |
| D1.0cc     | 72.3                               | 71.8            | 0.7          | 0.390    |         |
| D2.0cc     | 65.3                               | 65              | 0.5          | 0.372    |         |
| D4.0cc     | 57.1                               | 57              | 0.2          | 0.269    |         |
| D50%       | 12.3                               | 12              | 2.4          | 0.002    |         |

Table 2. Summary of statistics by parameter and tension applied to Foley catheter. *Normalized as percentage of prescribed dose. SD = standard deviation. DICRU = dose reported using ICRU bladder point visualized in CT plan.

---

| Parameters | Foley catheter tension (normalized*) | Standard tension | Extra tension | % change | p value |
|------------|-------------------------------------|-----------------|--------------|----------|---------|
| DICRU      | 44.6                               | 27.1            | 39.2         | <0.001   |         |
| Dmax       | 103.5                              | 98.3            | 5.0          | 0.016    |         |
| D0.1cc     | 88.1                               | 86.1            | 2.3          | 0.123    |         |
| D1.0cc     | 72.3                               | 71.8            | 0.7          | 0.390    |         |
| D2.0cc     | 65.3                               | 65              | 0.5          | 0.372    |         |
| D4.0cc     | 57.1                               | 57              | 0.2          | 0.269    |         |
| D50%       | 12.3                               | 12              | 2.4          | 0.002    |         |

Table 2. Summary of statistics by parameter and tension applied to Foley catheter. *Normalized as percentage of prescribed dose. SD = standard deviation. DICRU = dose reported using ICRU bladder point visualized in CT plan.
parameters and is essential for studies that use different doses per fraction, to make the results between studies comparable. In our data, the normalization was meant to account for differences in the prescription reference line, because patients who received VCB alone had 6 Gy/fraction prescribed to 0.5 cm from the cylinder surface, and those who received both VCB and EBRT were targeted at the surface.

Our group recently published a retrospective series on 126 patients who were treated with high-dose-rate VCB alone for intermediate-risk endometrial cancer with a 9.5% rate of grades 1 or 2 acute urinary toxicity and no case of grade 3 toxicity. We did not find any differences in bladder ICRU point doses between the asymptomatic group and symptomatic group, with 11.256 Gy × 11.952 Gy (p = 0.69), respectively. Additionally, the use of a Foley catheter was deemed to be responsible for part of the acute toxicity reported, due to an inherent increased risk of urinary tract infection. Despite the low rates of grades 3 and 4 urinary toxicity in the literature after VCB alone (<3%) and the combination with EBRT could lead to serious complications, like bowel perforation and urethral strictures. Additionally, the documentation of the previous treatment dose to OARs can more accurately define an opportunity for re-irradiation, in cases of recurrence.

Nevertheless, contrasting results have been reported by studies that have addressed the dosimetric difference of point versus dosimetric parameters in high-dose-rate brachytherapy for radical treatment of cervical cancer (intact uterus). Some studies suggest a tendency in the correlation, whereas others do not. Although our findings support the adoption of CT-based planning in VCB, its generalization to HDR in the intact uterus should be supported by specific studies.

Further, additional studies are necessary to identify better predictors of toxicity in HDR brachytherapy for the vaginal vault and for radical treatment of cervical cancer and inoperable endometrial cancer. In these settings, our findings might support future trial designs that include 3D planning. It might be better to define the extension of the vaginal vault and superior vaginal mucosa, leading to changes in the prescription method to volumetric instead of merely using a reference from the applicator surface or target surrogates.

In conclusion, the dose reported to the bladder using bladder D\textsubscript{ICRU} or D\textsubscript{max} is dependent on the tension of the balloon in VCB. Because volumetric parameters (D\textsubscript{0.1cc}, D\textsubscript{1.0cc} and D\textsubscript{2.0cc}) are independent of the anatomical changes due to the presence of a urinary catheter, they might be a better option. Further analysis of toxicity outcomes is needed to determine the most appropriate dose parameter.

**Methods**

**Patients.** The study recruited female patients aged between 18 and 85 years. The inclusion criteria were a histological diagnosis of cervical or endometrial cancer and a computed tomography scan (CT scan) that was available in the planning system. Patients who did not undergo oncological surgery as the initial treatment were excluded. The institutional review board, named Comitê de Ética em Pesquisa em Seres Humanos da Fundação Antônio Prudente, approved this study design and the use of patient information without name or facial identification. All patients signed informed consent forms before study entry. The protocol was registered earlier (NCT02091050), and the methods were carried out in accordance with the approved guidelines.

**Simulation and Insertions.** Before insertion of the applicator, a Foley catheter was inserted into the urethra, to report the ICRU bladder dose (D\textsubscript{ICRU}), as described in the ICRU 38 report, but adapted to the computed tomographic image. Briefly, on the sagittal view of the tomographic image, the bladder reference point was obtained on the posterior surface of the balloon, on an anterior-posterior line through the center of the balloon. On the coronal view, the reference point was defined as the center of the balloon, mimicking the position in the traditional simple x-ray image (Fig. 2a).

To test the robustness of the dose parameters, CT scan images were obtained in two scenarios: with the Foley catheter tensioned towards the caudal direction of the patient using standard tension and extra tension (Fig. 2b). Standard tension (position A) was defined as the tension that was necessary to position the balloon at the bladder trigone. Extra tension (position B) was defined as additional tension in the catheter, limited by the patient’s complaint of discomfort. The CT scan had the following characteristics: voltage 120 kV, current 275 mA and exposure 300 mAs. A manometer was not used to identify different tension levels. After insertion of the vaginal applicator, limited effort was made to correct the insertion angle to a central position in the pelvis before performing the CT-scan. It was not provided a specific instruction concerning bladder filling. Because the two images were taken in a short interval (less than 2 minutes), the volume of the bladder was considered to be constant between positions A and B (average 350.560.4 mL and 360.4 mL, respectively).

| Study            | Year | n     | Design                        | CT planning | Ratio D\textsubscript{max}/D\textsubscript{ICRU} | Ratio D\textsubscript{2cc}/D\textsubscript{ICRU} |
|------------------|------|-------|-------------------------------|-------------|-----------------------------------------------|-----------------------------------------------|
| Russo et al. 4   | 2012 | 71    | retrospective                 | every fraction | 1.79                                          | 1.08                                          |
| Hung et al. 8    | 2012 | 22    | 2D and 3D                     | prospective | 1st fraction only | 3.62                                          |
| present study    | 2015 | 22    | 2D and 3D                     | prospective | 1st fraction only | 3.62                                          |

Table 3. Design of published studies that have compared bladder D\textsubscript{ICRU} and other parameters in VCB.
Lateral and anteroposterior simple x-ray images were taken before each subsequent insertion to confirm the position of the cylinder, comparing the radiographic image with a digitally reconstructed radiograph (DRR) from the CT-scan in position A (Fig. 2c). Again, limited effort was made to correct the insertion angle, with posterior documentation of the final position with the other set of x-ray images. The lithotomy position was used only during insertion of the applicator, and the patients underwent the simulation and treatment with their legs extended.

**Prescription and Dosimetry.** The total dose was 24 Gy, delivered in 4 weekly fractions of 6 Gy (EQD2 38.4 Gy) to the cylinder surface in EBRT + VCB cases and 0.5 cm from the applicator surface in cases that were treated with VCB alone, to cover more of the mucosa. Because no patient presented with vaginal extension of the tumor, based on the pathological report, the cylinder was activated only at the proximal 2 cm, at the department's discretion.

The brachytherapy planning and dosimetric data were obtained from the treatment planning system (BrachyVision Eclipse®, version 11.0, Varian, Palo Alto, CA, USA), based on the CT-scan that was performed before the first procedure. The same physician contoured the OARs in all images. The dose parameters analyzed were: bladder reference point (DICRU); maximum bladder point (Dmax bladder); the minimum dose value in the 0.1 cc, 1.0 cc, 2.0 cc and 4.0 cc receiving the highest dose (D0.1cc, D1.0cc, D2.0cc, D4.0cc) and the dose that was received by 50% of the bladder (D50%).

The treatment was delivered using a GammaMedplus™ IX high-dose-rate device (VARIAN, Palo Alto, CA, USA), using the AAPM TG-43 formalism. The 192Ir Gammamed HDR plus source listed in the library of origin was used.

**Statistical analysis.** Visual observation of the histograms and Shapiro-Wilk's test (p > 0.05) were used to define the normality of the distribution of doses. Wilcoxon signed rank test was used to compare doses of non-normally distributed dependent variables. All statistical analyses were performed using IBM SPSS Statistics, version 20.0. Armonk, NY.

**References**

1. Klopp, A. et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. *Pract Radiat Oncol* 4, 137–144 (2014).
2. Chen, M. F. et al. Clinical outcome in post hysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. *Int J Radiat Oncol Biol Phys* 67, 1438–1444 (2007).
3. International Commission on Radiation Units & Measurements (ICRU)-Dose and volume specification for reporting intracavitary therapy in gynecology. Bethesda, MD. ICRU Report 38. Available at: http://www.icru.org/home/reports/dose-and-volume-specification-for-reporting-intracavitary-therapy-in-gynecology-report-38. (Accessed: 27 april 2016) (1985).
4. Potter, R. et al. Recommendations from gynecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose value parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. *Radiother Oncol* 78, 67–77 (2006).
5. Small Jr., W. et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. *Brachytherapy* 11, 58–67 (2012).
6. Russo, J. K., Armeson, K. E. & Richardson, S. Comparison of 2D and 3D imaging and treatment planning for postoperative vaginal apex high-dose-rate brachytherapy for endometrial cancer. *Int J Radiat Oncol Biol Phys* 83, e75–e80 (2012).
7. Barney, B. M., MacDonald, O. K., Lee, C. M., Rankin J. & Gaffney D. K. An analysis of simulation for adjuvant intracavitary high-dose-rate brachytherapy in early-stage endometrial cancer. *Brachytherapy* 6, 201–206 (2007).
8. Hung, J., Shen, S., de Los Santos, J. F. & Kim, R. Y. Image-based 3D treatment planning for vaginal cylinder brachytherapy: dosimetric effects of bladder filling on organs at risk. *Int J Radiat Oncol Biol Phys* 72, 843–848 (2012).
9. Stewart, A. J. et al. Prospective clinical trial of bladder filling and three-dimensional dosimetry in high-dose-rate vaginal cuff brachytherapy. *Int J Radiat Oncol Biol Phys* 72, 843–848 (2008).
10. Caon, J., Holloway, C., Dubash, R., Yuen, C. & Aquino-Parsons, C. Evaluating adjacent organ radiation doses from postoperative intracavitary vaginal vault brachytherapy for endometrial cancer. *Brachytherapy* 13, 94–99 (2014).
11. Sabater, S. et al. Dosimetric analysis of rectal filling on rectal doses during vaginal cuff brachytherapy. *Brachytherapy* 14, 458–463 (2015).
12. Holloway, C. L., Macklin, E. A., Cormack, R. A. & Viswanathan, A. N. Should the organs at risk be contoured in vaginal cuff brachytherapy? *Brachytherapy* 10, 313–317 (2011).
13. Rose, T. et al. Planning CT scans for the treatment of HDR vaginal vault brachytherapy: an evaluation of its role to determine the dose to the organs at risk. *Brachytherapy* 14, 584–585 (2015).
14. Demanes, D. J. et al. The use and advantages of a multichannel vaginal cylinder in high-dose-rate brachytherapy. *Int J Radiat Oncol Biol Phys* 44, 211–219 (1999).
15. Kim, H., Malolan, S., Rajagopalan, M. S., Houser C. & Beriwal, S. Dosimetric comparison of multichannel with one single-channel vaginal cylinder for vaginal cancer treatments with high-dose-rate brachytherapy. *Brachytherapy* 13, 263–267 (2014).
16. Sapienza, L. G. et al. Bladder (ICRU) dose point does not predict urinary acute toxicity in adjacent isolated vaginal vault high-dose-rate brachytherapy for intermediate-risk endometrial cancer. *J Contemp Brachytherapy* 7, 357–362 (2015).
17. Hoskin, P. J., Bownes, P. & Summers, A. The influence of applicator angle on dosimetry in vaginal vault brachytherapy. *Br J Radiol* 75, 234–237 (2002).
18. Corso, C. D. et al. Dosimetric and cost comparison of first fraction imaging versus fractional re-imaging on critical organ dose in vaginal cuff brachytherapy. *Pract Radiat Oncol* 3, 256–262 (2013).
19. Pelloski, C. E. et al. Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer. *Int J Radiat Oncol Biol Phys* 62, 131–137 (2005).
20. Yaparpalvi, R. et al. Point vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data. *Brachytherapy* 7, 336–342 (2008).
21. Patil, V. M., Patel, F. D., Chakraborty, S., Oinam, A. S. & Sharma, S. C. Can point doses predict volumetric dose to rectum and bladder: a CT-based planning study in high dose rate intracavitary brachytherapy of cervical carcinoma? *Br J Radiol* 84, 441–448 (2011).
22. Shapiro, S. S. & Wilk, M. B. An analysis of variance test for normality (complete samples). *Biometrika* 52, 591–611 (1965).
23. Wilcoxon, F. Individual comparisons by ranking methods. *Biometrics Bulletin* 1, 80–83 (1945).

**Acknowledgements**

The authors would like to thank the nursing staff from the radiology department and the medical dosimetrist for providing support on the treatment preparation. The study was supported by Ricardo Brentani Award, AC Camargo Cancer Center.

**Author Contributions**

L.G.S., R.C. and G.B. conceived of and designed the study. L.G.S., A.F. and A.A. performed the analyses. L.G.S., A.F., A.C.d.A.P. and G.B. prepared all figures and tables. L.G.S., R.C. and G.B. wrote the main manuscript. All authors reviewed the manuscript.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Sapienza, L. G. et al. Volumetric (3D) bladder dose parameters are more reproducible than point (2D) dose parameters in vaginal vault high-dose-rate brachytherapy. *Sci. Rep.* 6, 28074; doi: 10.1038/srep28074 (2016).